Arcus Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Arcus Biosciences, Inc. (RCUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $48.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2023-02-28
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $48.00M, a 20.00% increase from fiscal 2021.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $40.00M, a 135.29% increase from fiscal 2020.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $17.00M, a 117.95% increase from fiscal 2019.
- Arcus Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $7.80M, a 160.00% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|
| 2022-12-31 | $48.00M 10-K · filed 2023-02-28 | |
| 2021-12-31 | $40.00M 10-K · filed 2023-02-28 | $52.40M 10-K · filed 2022-02-23 |
| 2020-12-31 | $17.00M 10-K · filed 2023-02-28 | $16.80M 10-K · filed 2021-02-25 |
| 2019-12-31 | $7.80M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $3.00M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $500.00K 10-K · filed 2019-03-05 | |
| 2016-12-31 | $100.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |